Navigation Links
Boston Scientific Acquires Labcoat Limited

Acquisition demonstrates Company's commitment to innovation in drug-eluting stent technology

NATICK, Mass., Jan. 6 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has acquired Labcoat Limited, a privately held, development-stage drug-eluting stent technology company located in Galway, Ireland. Terms of the acquisition were not disclosed.

Labcoat has developed a novel technology for coating drug-eluting stents that uses precisely metered droplets of a biodegradable polymer and drug formulation to create a thin (< 1 micron) coating confined to the outer surface of a coronary stent. This proprietary technology is designed to significantly reduce the amount of polymer and drug to which the vessel wall is exposed, while minimizing polymer and drug on the inner surface of the stent where endothelial cell growth is required for healing. Once the drug has been delivered, the biodegradable coating resorbs, leaving behind only the bare-metal stent. This approach is intended to provide the same degree of restenosis reduction as a conventional drug-eluting stent, but faster and more complete vessel healing after stent implantation.

"Boston Scientific has enjoyed an ongoing, productive relationship with Labcoat, and we look forward to building on our shared commitment to developing new drug-eluting stent technologies that improve patient outcomes," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "This technology represents a major advance for drug-eluting stents and should help us maintain our strong position in this market."

Labcoat has successfully completed a clinical trial with its JACTAX(TM) Stent, which consists of a Boston Scientific bare-metal Liberte(R) Stent coated on its outer surface with a biodegradable polymer containing the drug paclitaxel. Clinical data presented at TCT 2008 showed promising results for both restenosis and strut coverage nine months after implantation. These data will be used to support CE Mark submission, which is expected to occur in the first half of this year. European launch of a new drug-eluting stent incorporating this technology is planned following regulatory approval.

Boston Scientific plans to evaluate the Labcoat technology for use on both its paclitaxel and everolimus families of drug-eluting stents.

Paclitaxel is employed on the TAXUS(R) family of stents, which have been studied in thousands of patients in clinical trials and implanted in approximately four million patients worldwide.

About Boston Scientific Corporation

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding new product development and performance, acquisitions and integration of acquired companies, development plans and expenditures, and our growth strategy. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    CONTACTS:              Paul Donovan
                           508-650-8541 (office)
                           508-667-5165 (mobile)
                           Media Relations
                           Boston Scientific Corporation

                           Larry Neumann
                           508-650-8696 (office)
                           Investor Relations
                           Boston Scientific Corporation

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Approves Boston Scientifics Express(R) SD Renal Stent System
2. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
3. Boston Scientific to Participate in Piper Jaffray Health Care Conference
4. Trusted LASIK Surgeons Welcomes LASIK Expert Michael Raizman of Boston to its Unique LASIK Directory
5. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
6. FDA Approves Boston Scientifics Apex(TM) PTCA Dilatation Catheter
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability
9. Boston Scientific Announces Results for Third Quarter Ended September 30, 2008
10. Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet
11. Boston Scientific Provides Update on Involuntary Selling of Its Stock by Co-Founders
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... ... systems, material handling solutions and components, is opening its latest Parker Store retail ... the facility is Exotic’s second major expansion in Metropolitan Detroit in less than ...
(Date:10/13/2015)... ... October 13, 2015 , ... SonaCare Medical, ... today that it received de novo clearance from the U.S. Food and Drug ... ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) ...
(Date:10/13/2015)... ... October 13, 2015 , ... The New ... age children in the areas of Science, Technology, Engineering and Mathematics. The skill ... economy, and the program aims to increase the number of students who pursue ...
(Date:10/12/2015)... BRUSSELS , Oct. 12, 2015  Amgen (NASDAQ: ... additional findings from an exploratory sub-study of the previously reported ... today in an oral plenary session at the American Society ... Seattle . 2 ... small exploratory sub-study data showed that, at month 12, the ...
Breaking Biology Technology:
(Date:10/12/2015)... --> --> ... the "Digital Security Control Market by Hardware (Smart Card, ... (Anti-Phishing, Authentication, Network Surveillance, & Others), Service, Application, and ... market is expected to grow at a CAGR of ... Billion by 2020. Browse 65 market data ...
(Date:10/9/2015)... 09 2015 ... the "Samsung Galaxy S6 Fingerprint Sensor ... their offering. --> ) ... "Samsung Galaxy S6 Fingerprint Sensor - Reverse ... --> Research and Markets ( ...
(Date:10/7/2015)... NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... long- term executive at American Express has been appointed ... ) ("NXT-ID" or the "Company"), a biometric authentication company ... of the Wocket® smart wallet announces Mr. Stanley ...
Breaking Biology News(10 mins):